|
Q1 2024
|
42 |
1,272,571 |
SLNO, GERN, HRMY, SINX
|
13F-HR
|
4/22/2024 |
000121390024034979 |
|
Q4 2023
|
47 |
1,221,329 |
SLNO, GRCL, I9SA.HA, HRMY
|
13F-HR
|
2/6/2024 |
000121390024010646 |
|
Q3 2023
|
53 |
912,764 |
GTH, SLNO, HRMY, I9SA.HA
|
13F-HR
|
11/8/2023 |
000121390023084732 |
|
Q2 2023
|
48 |
1,448,793 |
SINX, HRMY, I9SA.HA, AVDL
|
13F-HR
|
8/14/2023 |
000121390023067000 |
|
Q1 2023
|
48 |
1,441,130 |
SINX, GTH, I9SA.HA, HRMY
|
13F-HR
|
5/15/2023 |
000121390023039212 |
|
Q4 2022
|
48 |
868,545 |
HRMY, TERN, VRDN, ALXO
|
13F-HR
|
2/13/2023 |
000121390023010818 |
|
Q3 2022
|
51 |
905,807 |
HRMY, TIL, VTYX, I9SA.HA
|
13F-HR
|
11/14/2022 |
000121390022072092 |
|
Q2 2022
|
49 |
995,881 |
HRMY, SRRA, TIL, ISEE
|
13F-HR
|
8/15/2022 |
000121390022047557 |
|
Q1 2022
|
54 |
1,452,156 |
HRMY, New Frontier Health Corp, TIL, ISEE
|
13F-HR
|
5/13/2022 |
000121390022026422 |
|
Q4 2021
|
55 |
1,658,443 |
TIL, HRMY, New Frontier Health Corp, ISEE
|
13F-HR
|
2/11/2022 |
000121390022006960 |
|
Q3 2021
|
60 |
2,227,158 |
ALXO, TIL, HRMY, New Frontier Health Corp
|
13F-HR
|
11/15/2021 |
000121390021059130 |
|
Q2 2021
|
59 |
2,310,071 |
TIL, ALXO, ASND, AMRS
|
13F-HR
|
8/16/2021 |
000121390021042960 |
|
Q1 2021
|
63 |
2,845,273 |
TIL, ALXO, AMRS, ASND
|
13F-HR
|
5/17/2021 |
000121390021026949 |
|
Q4 2020
|
59 |
2,240,895 |
ALXO, ASND, HRMY, TARS
|
13F-HR
|
2/16/2021 |
000121390021009490 |
|
Q3 2020
|
64 |
1,730,387 |
ASND, ALXO, HRMY, NEW FRONTIER HEALTH CORP
|
13F-HR
|
11/13/2020 |
000121390020036943 |
|
Q2 2020
|
54 |
1,394,707 |
ASND, LEGN, New Frontier Health Corp, GTH
|
RESTATEMENT
|
11/13/2020 |
000121390020036945 |
|
Q1 2020
|
53 |
1,103,888 |
ASND, New Frontier Health Corp, KDMN, ARQT
|
13F-HR
|
5/15/2020 |
000121390020012587 |
|
Q4 2019
|
49 |
1,372,681 |
Ascendis Pharma A/S, New Frontier Health Corp, Aurinia Pharmaceuticals Inc., Crinetics Pharmaceuticals Inc
|
RESTATEMENT
|
2/25/2020 |
000121390020004679 |
|
Q3 2019
|
49 |
878,828 |
Ascendis Pharma A/S, Arrowhead Pharmaceuticals Inc, Crinetics Pharmaceuticals Inc, Tricida, Inc.
|
13F-HR
|
11/13/2019 |
000121390019023217 |
|
Q2 2019
|
46 |
1,067,129 |
ASND, CRNX, ARWR, TCDA
|
13F-HR
|
8/13/2019 |
000121390019015546 |
|
Q1 2019
|
49 |
1,002,882 |
ASND, CRNX, CDXS, ARWR
|
13F-HR
|
5/14/2019 |
000161577419007680 |
|
Q4 2018
|
45 |
783,077 |
ASND, CRNX, Biohaven Pharmaceutical Holding Company Ltd, CDXS
|
13F-HR
|
2/13/2019 |
000161577419002398 |
|
Q3 2018
|
44 |
992,161 |
ASND, CRNX, Biohaven Pharmaceutical Holding Company Ltd, CDXS
|
13F-HR
|
11/13/2018 |
000161577418012532 |
|
Q2 2018
|
40 |
776,070 |
ASND, Biohaven Pharmaceutical Holding Company Ltd, KDMN, CDXS
|
13F-HR
|
8/10/2018 |
000161577418007846 |
|
Q1 2018
|
34 |
705,919 |
VYNE, ASND, Biohaven Pharmaceutical Holding Company Ltd, CDXS
|
13F-HR
|
5/15/2018 |
000121465918003735 |
|
Q4 2017
|
30 |
466,864 |
ASND, Biohaven Pharmaceutical Holding Company Ltd, ACRS, APLS
|
13F-HR
|
2/9/2018 |
000121465918001028 |
|
Q3 2017
|
29 |
494,813 |
Biohaven Pharmaceutical Holding Company Ltd, ACRS, ASND, NBRV
|
13F-HR
|
11/13/2017 |
000121465917006608 |
|
Q2 2017
|
26 |
397,070 |
ACRS, Biohaven Pharmaceutical Holding Company Ltd, ASND, NBRV
|
13F-HR
|
8/2/2017 |
000121465917004735 |
|
Q1 2017
|
23 |
339,946 |
ACRS, ASND, NBRV, CDXS
|
13F-HR
|
5/15/2017 |
000121465917003338 |
|
Q4 2016
|
25 |
303,451 |
ACRS, ASND, CDXS, NBRV
|
RESTATEMENT
|
4/6/2017 |
000121465917002413 |
|
Q3 2016
|
22 |
320,887 |
ACRS, ASND, EIGR, CDXS
|
13F-HR
|
11/14/2016 |
000121465916014565 |
|
Q2 2016
|
23 |
366,183 |
SGNT, ACRS, EIGR, NBRV
|
13F-HR
|
8/15/2016 |
000121465916013202 |
|
Q1 2016
|
24 |
398,682 |
ACRS, SGNT, Biotie Therapies Corp., NBRV
|
13F-HR
|
5/16/2016 |
000121465916011605 |